A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Trial Profile

A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Selinexor (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Jun 2017 Status changed from suspended to recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 09 Mar 2017 Status changed from recruiting to suspended due to pending amendment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top